第85回日本血液学会学術集会が、2023/10/13-16の日程にて東京国際フォーラムで開催され、CML-CSGより6演題を口説として報告しました。抄録などの詳細は、それぞれの発表をクリックしてください。
★ O1-pm2-8#2
Second malignancies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
○Hitomi Nakayama, Tomonori Nakazato, Noriyoshi Iriyama, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Eisaku Iwanaga, Tatsuya Kawaguchi.
★ O2-pm1-11#1
Pregnancy and childbirth in patients with chronic myeloid leukemia in real-life practice
○Eriko Sato, Eisaku Iwanaga, Maho Ishikawa, Tomoiku Takaku, Noriyoshi Iriyama, Takayuki Tabayashi, Yuta Kimura, Michihide Tokuhira, Naoki Watanabe, Toru Mitsumori, Tomonori Nakazato, Hitomi Nakayama, Hiroyuki Fujita, Miki Ando, Tatsuya Kawaguchi.
★ O2-pm2-11#2
Outcomes of CML patients not achieving optimal response at one year of TKI treatment
○Eisaku Iwanaga, Noriyoshi Iriyama, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Tomonori Nakazato, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Tatsuya Kawaguchi.
★ O2-pm2-11#3
Usefulness of new risk prediction model for VAEs in Japanese patients with CML treated with TKIs
○Naoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, Yuta Kimura, Eisaku Iwanaga, Toru Mitsumori, Maho Ishikawa, Hitomi Nakayama, Tomonori Nakazato, Hiroyuki Fujita, Eriko Sato, Takayuki Tabayashi, Michihide Tokuhira, Miki Ando, Tatsuya Kawaguchi.
★ O2-pm2-11#5
The effect of introduction of 2G-TKI as first-line therapy on CML treatment modalities and outcomes
○Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, Tomonori Nakazato, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Yoshihiro Hatta, Tatsuya Kawaguchi.
